Simulations PlusFRA:SD3 67 Pretax Margin % is 24.23% as of Feb. 2026, which is 13% below its 10-year median of 27.71. GuruFocus rates FRA:SD3 with a GF Score™ of 67/100 and a GF Value™ of €32.93 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 664 Healthcare Providers & Services companies, Simulations Plus ranks worse than 89.31% on this metric.
The historical rank and industry rank for Simulations Plus's Pretax Margin % or its related term are showing as below:
FRA:SD3'
s Pretax Margin % Range Over the Past 10 Years
Min: -87.62 Med: 27.71 Max: 36.23
Current: -82.32
FRA:SD3's Pretax Margin % is ranked worse than 89.31% of 664
companies
in the Healthcare Providers & Services industry
Industry Median: 4.01
vs FRA:SD3: -82.32
Simulations Plus (FRA:SD3) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Simulations Plus Pretax Margin % Related Terms
Simulations Plus Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Simulations Plus's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:SD3 vs TBRG, CARL, NRC: Pretax Margin % Comparison
For the Health Information Services subindustry, Simulations Plus's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Simulations Plus Pretax Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Simulations Plus's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Simulations Plus's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Simulations Plus (FRA:SD3) has a Pretax Margin % of 24.23% as of Feb. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Simulations Plus and its competitors. This is 13% below median its historical median of 27.71. According to the industry distribution chart, Simulations Plus ranks #593 out of 664 companies in the Healthcare Providers & Services industry, placing it in the top 89.3%.
Is Simulations Plus' Pretax Margin % too high?
Simulations Plus' current Pretax Margin % of 24.23% is 13% below median its 10-year median of 27.71. The Healthcare Providers & Services industry median Pretax Margin % is 4.01. Simulations Plus' value of 24.23% is 504.2% above this industry median. Based on the distribution chart, Simulations Plus ranks #593 out of 664 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Simulations Plus has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Simulations Plus' Pretax Margin % compare to TBRG and CARL?
According to the Healthcare Providers & Services industry distribution chart, Simulations Plus ranks #593 out of 664 companies for Pretax Margin %. This places Simulations Plus in the lower half of its industry. The industry median Pretax Margin % is 4.01. Simulations Plus' value of 24.23% is 504.2% above this benchmark. While the company's 10-year median is 27.71 vs. the industry median of 4.01, Simulations Plus has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Healthcare Providers & Services company?
The median Pretax Margin % among Healthcare Providers & Services companies is 4.01, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Simulations Plus's current Pretax Margin % of 24.23% is 504.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Simulations Plus and its competitors. For the Healthcare Providers & Services industry, the median Pretax Margin % is 4.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Simulations Plus's current Pretax Margin % is 24.23%, which is 13% below median its own 10-year median of 27.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simulations Plus stock overvalued right now?
Based on GuruFocus' analysis, Simulations Plus (FRA:SD3) is currently considered Significantly Undervalued. The stock's GF Value™ is €32.93, compared to a current price of €15.80 — trading 52% below its estimated fair value. The current Pretax Margin % is 24.23%, which is 13% below median its 10-year median of 27.71 and 504.2% above the Healthcare Providers & Services industry median of 4.01. Simulations Plus' overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Simulations Plus (FRA:SD3), the current Pretax Margin % is 24.23% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Simulations Plus (FRA:SD3) Overvalued in 2026?
Based on GuruFocus' analysis, Simulations Plus stock appears to be undervalued.
The current stock price of €15.80 is trading 52% below its estimated GF Value™ of €32.93.
GuruFocus considers Simulations Plus to be Significantly Undervalued.
Key valuation signals for FRA:SD3:
Pretax Margin %: 24.23% (13% below median its 10-year median of 27.71)
GF Value™: €32.93 vs. price of €15.80 (52% below fair value)
Industry Position: 504.2% above the Healthcare Providers & Services median (#593 of 664)
No single metric tells the full story. See the FRA:SD3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
67GF Score
Get the complete analysis for FRA:SD3
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:SD3 has been successfully added to your 
